Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2155910 | 0.83 | HTT (0.38) | HTTEPHX2ACHE | |
| SCHEMBL262398 | 0.79 | HTT (0.36) | HTTEPHX2 | |
| SCHEMBL16689618 | 0.79 | HTT (0.36) | HTTEPHX2 | |
| SCHEMBL1443822 | 0.75 | HTT (0.37) | HTTEPHX2 | |
| SCHEMBL2154988 | 0.75 | HTT (0.33) | HTTEPHX2 | |
| SCHEMBL17032653 | 0.72 | HTT (0.33) | HTT | |
| SCHEMBL14822032 | 0.71 | HTT (0.37) | HTTEPHX2ACHE | |
| SCHEMBL2237839 | 0.67 | HTT (0.34) | HTTACHE | |
| SCHEMBL2986780 | 0.67 | CHRM1 (0.35) | HTT | |
| SCHEMBL18307749 | 0.66 | TSHR (0.36) | HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188141-B2 | Isomigrastatin analogs in the treatment of cancer | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188141-B2 | Isomigrastatin analogs in the treatment of cancer | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090054488-A1 | Isomigrastatin Analogs In The Treatment Of Cancer | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-02-26 | — | — | US | disclosed |
| US-20090054488-A1 | Isomigrastatin Analogs In The Treatment Of Cancer | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054488-A1 | Isomigrastatin Analogs In The Treatment Of Cancer | EDNRB, KDR, IGF1R | HTT 4495/4885EPHX2 3168/4885ACHE 1781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.